AVLN AVALYN PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, AVALYN PHARMACEUTICALS INC reported revenue of n/a, net income of −$28.9M and diluted EPS of −$0.98.
AVLN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$28.9M, EPS −$0.98
- Quarter ended Mar 31, 2026: revenue n/a, net income −$26.9M, EPS −$21.83
- Quarter ended Jun 30, 2025: revenue n/a, net income −$20.2M, EPS −$17.63
- Quarter ended Mar 31, 2025: revenue n/a, net income −$17.5M, EPS −$63.24
AVLN balance sheet
- Jun 30, 2026: cash $264M, total assets $425M, total liabilities $27.1M, shareholders' equity $398M, long-term debt $14.8M
- Mar 31, 2026: cash $92.3M, total assets $136M, total liabilities $27.7M, shareholders' equity −$264M, long-term debt $14.8M
- Dec 31, 2025: cash $52.3M, total assets $149M, total liabilities $15.3M, shareholders' equity −$239M, long-term debt $0